2025 ASCO GU Symposium - TCAF's Meet & Greet Social

On February 13, 2025, Testicular Cancer Awareness Foundation (TCAF) hosted a Meet & Greet at the speakeasy-style venue, Marianne’s, in San Francisco. The social was sponsored by Fennec Pharmaceuticals and took place during the 2025 ASCO Genitourinary Cancers Symposium, attracting over 50 attendees, including leading urologic oncologists and researchers in the field of testicular cancer.

TCAF’s Meet & Greet Socials are a great opportunity for experts in the testicular cancer field to connect, exchange ideas, and collaborate on advancements in care and research. Bringing together these professionals in a more informal setting can foster meaningful relationships that lead to impactful breakthroughs in the treatment and understanding of testicular cancer; it will help shape the future of care and treatments for their patients.

For TCAF, hosting events like this provides an opportunity to share our resources and programs that we provide to patients and their families. Together, we are making a positive, impactful difference in the fight against testicular cancer.

Thanks to our newest Cause Marketing Partner, some of our guests left with CaddySack gifts - CaddySack has joined forces with TCAF in support the fight against testicular cancer bringing humor and heart to the golf course while supporting early detection and education for this disease.

We also provided educational materials, and "Survivor" wristbands for their patients. These small gestures are part of TCAF's ongoing commitment to supporting patients and raising awareness about testicular cancer.

Special thanks to Fennec Pharmaceuticals for sponsoring this great event as well as their continued support in advancing our mission. Guests also got to learn about Fennec’s Pedmark product; Fennec offers the first and only FDA approved hearing loss prevention for adolescents and young adults (AYA) who receive cisplatin chemotherapy to help reduce ototoxicity (hearing loss).

Special thanks to Fennec Pharmaceuticals for sponsoring this great event as well as their continued support in advancing our mission and most recently being the presenting sponsor of the 2024 Testicular Cancer Conference.

Fennec offers the first and only FDA approved hearing loss prevention for adolescents and young adults (AYA) who receive cisplatin chemotherapy to help reduce ototoxicity (hearing loss). Fennec’s hearing loss drug, Pedmark, is also recommended by the NCCN guidelines for patients 15-39 years of age. If you are about to start treatment for testicular cancer that includes cisplatin chemotherapy, contact Fennec HEARS at 1-833-7PEDMARK or 1-(833)-773-3627.

TCAF looks forward to attending more oncology and urology conferences and continuing to bring the community together. Stay tuned for more opportunities to engage with us in the fight against testicular cancer!